Tilray (NASDAQ:TLRY) Vs. CGC, USNA, CRON, ACB, SNDL, CDXC, HEXO, IMCC, NAII, and MDWD
Should you be buying Tilray stock or one of its competitors? The main competitors of Tilray include Canopy Growth (CGC), USANA Health Sciences (USNA), Cronos Group (CRON), Aurora Cannabis (ACB), Sundial Growers (SNDL), ChromaDex (CDXC), HEXO (HEXO), IM Cannabis (IMCC), Natural Alternatives International (NAII), and MediWound (MDWD). These companies are all part of the "medicinals & botanicals" industry.
Tilray vs.
USANA Health Sciences (NYSE:USNA) and Tilray (NASDAQ:TLRY) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, analyst recommendations, community ranking, institutional ownership and risk.
Tilray received 72 more outperform votes than USANA Health Sciences when rated by MarketBeat users. Likewise, 61.47% of users gave Tilray an outperform vote while only 61.06% of users gave USANA Health Sciences an outperform vote.
USANA Health Sciences has a beta of 0.85, indicating that its stock price is 15% less volatile than the S&P 500. Comparatively, Tilray has a beta of 2.39, indicating that its stock price is 139% more volatile than the S&P 500.
In the previous week, Tilray had 27 more articles in the media than USANA Health Sciences. MarketBeat recorded 30 mentions for Tilray and 3 mentions for USANA Health Sciences. USANA Health Sciences' average media sentiment score of 0.84 beat Tilray's score of 0.33 indicating that USANA Health Sciences is being referred to more favorably in the media.
54.8% of USANA Health Sciences shares are held by institutional investors. Comparatively, 12.1% of Tilray shares are held by institutional investors. 0.2% of USANA Health Sciences shares are held by insiders. Comparatively, 3.2% of Tilray shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
USANA Health Sciences has higher revenue and earnings than Tilray. Tilray is trading at a lower price-to-earnings ratio than USANA Health Sciences, indicating that it is currently the more affordable of the two stocks.
USANA Health Sciences has a net margin of 11.05% compared to Tilray's net margin of -66.64%. USANA Health Sciences' return on equity of 32.68% beat Tilray's return on equity.
USANA Health Sciences presently has a consensus target price of $124.00, indicating a potential upside of 22.47%. Tilray has a consensus target price of $12.54, indicating a potential upside of 82.80%. Given Tilray's higher possible upside, analysts clearly believe Tilray is more favorable than USANA Health Sciences.
Summary
USANA Health Sciences beats Tilray on 10 of the 18 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding TLRY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment >-1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tilray (NASDAQ:TLRY) vs. Its Competitors
Tilray Competitors List
